Biocon Limited has informed the Exchange regarding Board meeting held on May 08, 2025.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's board, meeting on May 8, 2025, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Consolidated Q4 revenue from operations rose about 13% year-on-year to Rs. 44,170 million, while net profit for the quarter more than doubled to Rs. 4,594 million. For the full year FY25, consolidated revenue grew modestly to Rs. 1,52,617 million and net profit rose around 10% to Rs. 14,294 million. The Biosimilars and Generics segments were the key growth contributors, with Research Services also posting healthy gains. Standalone FY25 net profit of Rs. 6,093 million looks much stronger than the previous year largely because of a one-time exceptional gain of Rs. 6,075 million from selling a part of the Syngene stake. The board also recommended a final dividend of Re. 0.50 per share (10% on face value of Rs. 5), with July 4, 2025 as the record date.
Shareholders will get a small but confirmed dividend; record date is July 4, 2025 with payment by September 5, 2025. The Q4 earnings beat looks strong on the surface, but most of the standalone profit boost comes from a one-time Syngene stake sale, so the underlying business performance is steadier than the headline suggests. Biosimilars remains the main growth engine, supported by recent debt refinancing and the Eris Lifesciences deal, which should be positives for the stock.